Faeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026
Key Highlights
- ➤PIKTOR preclinical poster will test monotherapy and combinations in HR+/HER2- breast cancer models
- ➤PIKTOR will be compared head-to-head with gedatolisib in two breast cancer xenograft models
- ➤PIKTOR suppressed PAM pathway nodes, including AKT, at comparable or higher rates versus single-node inhibitors
- ➤FTH-PIK-201 endometrial cancer Phase 2 topline data anticipated by year-end 2026
- ➤FTH-PIK-101 breast cancer Phase 1b/2 interim data anticipated in 2027
Expert Statements
Oliver Maddocks, Co-Founder and Chief Scientific Officer of Faeth Therapeutics
“PIKTOR”
Faeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026
* Poster will characterize the efficacy of PIKTOR as a monotherapy and in combination with fulvestrant, oral SERDs, and CDK inhibitors in preclinical models of breast cancer * Poster also includes results from head-to-head comparisons with gedatolisib, another multi-nodal inhibitor of the PI3K-AKT-mTOR (PAM) pathway, in preclinical breast cancer xenograft models * The poster will be presented on Friday, October 23 at 15:15 CEST (9:15 a.m. ET). These preclinical data are intended to inform ongoing clinical development in the FTH-PIK-101 trial Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it will present preclinical data at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.
Get started
Create a free account to read the full story.